Medicines for Malaria Venture
Dianah Otiend, a pregnant woman in Homa Bay, Kenya.
Turning milestones into momentum towards a malaria-free world
In 2025, the global response to malaria was marked by both real challenges and hard-won gains. As you explore this report, we invite you to see how individual achievements connect into a broader story: an organization grounded in science, guided by equity and focused on turning milestones into momentum towards a malaria‑free world.
Latest news and views
Invest in impact
Malaria is preventable and treatable, yet it still takes lives every day. Drug resistance is rising, while climate pressures, fragile health systems and funding challenges are making malaria more complex to control and eliminate.
The next generation of malaria medicines must be simpler to deliver and use in real-world settings, making treatment easier to complete and protection easier to sustain.
Every $1 invested in MMV-supported malaria medicines delivers an estimated $13 in health benefits. The focus is clear: innovate to eliminate.
Upcoming events
Explore the business plan to cure, prevent and eliminate malaria.
Spotlight on equity
Gender equity: Antimalarials for pregnant women
Women and girls are uniquely affected by malaria's health, economic and societal impacts. Malaria means a heightened risk of morbidity and mortality for pregnant women and girls and their newborns. This, in turn, contributes to keeping women and girls away from school and work, exacerbating gender inequalities in education and in the workplace, and ultimately intensifying gendered power imbalances in society. Read more about antimalarial drugs for pregnant women and how MMV works to remedy this with the Malaria in Mothers and Babies (MiMBa) strategy.
Equitable partnerships: MMV's approach
MMV’s equitable partnerships strategy aims to promote local ownership of R&D processes, expand clinical trial capacity and strengthen local research infrastructure, thus delivering sustainable impact. MMV successfully supports locally led partnerships (where endemic countries lead the decision-making) and co-creation partnerships (where decision-making is shared with partners) every step of the way – from conducting drug trials and bolstering clinical trial capacity, through working with pharmaceutical manufacturers, to generating evidence to steer policy change. MMV has identified four pillars of work to strengthen equitable partnerships in the Global South:
1. People (sustainable capacity strengthening)
2. Discovery, chemistry and manufacturing
3. Clinical strategy
4. Communication and advocacy
